سعر فوليتروب 150 وحدة دولية حقنة مملوءة 150 وحدة دولية/0.3 مل 2022

Recombinant human follicle-stimulating hormone 150 IU in 0.3 ml clear prefilled glass syringe with needle (LG Chem), 1 syringe per box; store at 2-8°C protected from light, do not freeze.

• Controlled ovarian hyperstimulation to mature multiple follicles during an assisted reproduction programme (IVF/ET, GIFT, ZIFT, ICSI).Population: Women with infertilityLG Chem
• Anovulation not treated with clomiphene citrate (WHO group II patients with polycystic ovary disease).Population: Women with infertilityLG Chem

• Most common (>=5%): ovulation induction - headache, abdominal pain, ovarian hyperstimulation; ART - abdominal pain, nausea, abdominal enlargement, headache, injection-site bruising.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Contraindicated with prior hypersensitivity to recombinant FSH products; high FSH levels indicating primary gonadal failure; uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary); sex hormone-dependent tumours of the reproductive tract; pituitary or hypothalamic tumours; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement not due to PCOS.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Should be used only by physicians experienced in infertility treatment with appropriate monitoring; can cause ovarian hyperstimulation syndrome (OHSS) with or without pulmonary or vascular complications, abnormal ovarian enlargement, ovarian torsion and multi-fetal gestation; hypersensitivity reactions including anaphylaxis have been reported. Use the lowest effective dose.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Ectopic pregnancy and spontaneous abortion risks may be increased in women treated with gonadotropins/ART; congenital malformations and ovarian neoplasms are addressed in the label warnings.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Not indicated in pregnant women; there are no human data that gonadotropins alone or as part of IVF/ICSI increase the risk of congenital malformations.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; women are advised not to breastfeed during treatment because prolactin secretion can reduce ovarian response.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

English text not available for this section.